Repatriation Medical Authority - Notice of Investigation - Chemically-acquired brain injury caused by mefloquine, tafenoquine or primaquine

Overview

The Veterans' Entitlements Act 1986 (VEA) was enacted to provide various forms of support and entitlements to Australian Defence Force veterans and their families. The legislation was introduced to address the need for a comprehensive legal framework that ensures veterans and their families receive appropriate compensation, pensions, and healthcare services. The VEA is administered by the Commonwealth Parliament, which established it to fill the gap in recognising and supporting the unique needs of veterans. The policy objective of the VEA is to provide fair and timely assistance to veterans, ensuring they receive the respect and support they deserve for their service. The Repatriation Medical Authority (the Authority) under the VEA has issued a notice of investigation concerning chemically-acquired brain injury caused by specific medications, namely mefloquine, tafenoquine, and primaquine. The Authority aims to determine if these conditions can be considered war-caused, defence-caused, a service injury, a service disease, or a service death. This investigation seeks to identify whether Statements of Principles should be determined to address these injuries. The Authority invites submissions from eligible individuals and organisations, including those with relevant expertise, to contribute to this investigation. Submissions must be made by 19 May 2017, either electronically via the RMA website or by email and post. This process ensures that all stakeholders have an opportunity to provide their insights and evidence to inform the Authority's findings.

Scope and Application

The Repatriation Medical Authority (the Authority) under section 196G of the Veterans' Entitlements Act 1986 (the VEA) has issued a notice of its intention to conduct an investigation into whether Statements of Principles may be determined in respect of chemically-acquired brain injury caused by mefloquine, tafenoquine or primaquine. This investigation pertains to individuals who may have suffered such injuries or death, and seeks to determine the extent to which these injuries or deaths may be considered war-caused, defence-caused, a service injury, a service disease, or a service death. The Authority extends an invitation to various persons and organisations, including those eligible to make a claim for pension or compensation, representatives of veterans and other relevant groups, and experts in relevant fields, to submit written evidence in relation to the investigation. Submissions can be made electronically via the RMA website or by email or post, and all submissions must be received by the Authority no later than 19 May 2017. This investigation is bound by the provisions of the VEA and is not subject to any exclusions or exemptions specified in the notice, although the Authority may extend or restrict its application through subordinate instruments.

Key Provisions

The notice of investigation under section 196G of the Veterans' Entitlements Act 1986 (VEA) (paragraph 1) mandates that the Repatriation Medical Authority (the Authority) is undertaking an investigation to determine whether Statements of Principles may be made regarding chemically-acquired brain injury caused by mefloquine, tafenoquine, or primaquine (subsection 196B(4) of the VEA). This investigation is aimed at discovering whether these types of injuries can be attributed to service or war, and to what extent. The Authority seeks written submissions from specific stakeholders, including those eligible for pensions or compensation, organisations representing veterans or members of the forces, relevant government bodies, and experts in related fields (paragraph 2). The first meeting of the investigation is scheduled for 6 June 2017. Submissions must be submitted by 19 May 2017, either electronically via the RMA website, by email, or by post, in accordance with the RMA Submission Guidelines available online (paragraph 3). The obligations imposed on the relevant parties by this Act are primarily centred around the provision of information and participation in the investigation process. Eligible claimants, representative organisations, and experts are mandated to submit written submissions to the Authority by the specified deadline (paragraph 2). The Repatriation Commission and Military Rehabilitation and Compensation Commission are also required to contribute to the investigation. The Authority is responsible for coordinating the investigation, reviewing the submissions, and determining whether Statements of Principles should be issued (subsection 196B(4) of the VEA). Failure to comply with the requirements of the Act can lead to various consequences. While the Act does not explicitly state civil or criminal penalties for non-compliance, the failure to submit required information or participate in the investigation process could result in the Authority determining that there is insufficient evidence to support Statements of Principles for the chemically-acquired brain injuries in question. This could potentially impact the eligibility of claimants for pensions, compensation, or other benefits related to their injuries. Furthermore, the Act's provisions are designed to ensure that all relevant information is considered in the investigation, so non-compliance may also lead to delays or inefficiencies in the process.